secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001437749-23-023047
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q2 net loss narrows to $9.9M; cash $58.7M after $65M private placement
--------------------------------------------------------------------------------

- GAAP net loss ($9.9M) vs ($14.0M) YoY; Non-GAAP net loss ($8.5M) vs ($11.9M).
- Cash totaled $58.7M at June 30, 2023, up from $14.8M a year ago; Q2 warrant exercises added $14.6M gross.
- Closed $65M private placement with Executive Chairman Robert Duggan, cancelling all debt owed to him.
- Preclinical: nsPFA cardiac clamp ablates 25mm tissue in 1.25 sec; catheter isolates pulmonary veins in ~5 sec.
- First-in-human study of nsPFA for benign thyroid nodules showed positive safety and tissue response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774923023047/0001437749-23-023047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774923023047/plse20230809_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer